Prognosis following transcatheter arterial embolization for 121 patients with unresectable hepatocellular carcinoma with or without a history of treatment

瞄准：回顾地为 HCC 后面的 transcatheter 与肝细胞癌(HCC ) 评估病人的预后与或没有治疗的历史动脉的 embolization (TAE ) 。方法：有在我们的医院里从 1992 ～ 2004 与 TAE 对待的 HCC 的 121 个病人在这研究被注册。84 个病人为 HCC 有治疗的历史，当时 37。在入口，有额外肝的转移的病人，门静脉肿瘤血栓，或孩子呸班的时候， C 被排除。当 HCC 的复发被提高的肿瘤标记，或 ultrasonography 或动态计算断层摄影术调查结果诊断时， TAE 被重复。结果：肿瘤尺寸更大，没有过去的治疗(P【0.01 ) ，肿瘤的数字是在病人的少数。然而，在节点转移(TNM ) 舞台或幸存在 2 个组之间评估的肿瘤没有差别。一个双性人 alpha-fetoprotein (法新社)(】100 ng/mL ) 的小叶片的肿瘤和高水平是与在有 HCC 的历史的病人的差的预后有关的因素。结论：预后追随者 TAE 在有或没有过去的治疗的 HCC 病人之间是类似的。在到一堂重复 TAE 功课的入口能改进预后以前， HCC 或周期性的 HCC 和获得的好本地人的早诊断对 HCC 控制。

AIM： To retrospectively evaluate the prognosis of patients with hepatocellular carcinoma （HCC） with or without a history of therapy for HCC following transcatheter arterial embolization （TAE）. METHODS： One hundred and twenty-one patients with HCC treated with TAE from 1992 to 2004 in our hospital were enrolled in this study. Eighty-four patients had a history of treatment for HCC, while 37 did not. At the time of entry, patients with extra-hepatic metastasis, portal vein tumor thrombosis, or Child-Pugh class C were excluded. TAE was repeated when recurrence of HCC was diagnosed by elevated tumor markers, or ultrasonography or dynamic computed tomography findings. RESULTS： Tumor size was larger and the number of tumors was fewer in patients without past treatment （P〈0.01）. However, there were no differences in tumor node metastasis （TNM） stage or survival rate between the 2 groups. A bilobular tumor and high level of α-fetoprotein （AFP） （〉100 ng/mL） were factors related to a poor prognosis in patients with a history of HCC. CONCLUSION： The prognosis following TAE is similar between HCC patients with and without past treatment. Early diagnosis of HCC or recurrent HCC and obtaining good local control against HCC before entry to a repeated TAE course can improve prognosis.